Valsartan for prevention of recurrent atrial fibrillation

New England Journal of Medicine

Volumn 360, Issue 16, 2009, Pages 1606-1617

  Delise, P ^a   Bertocchi, F ^a   Maiocchi, G ^a   Geraci, E ^a   Correale, E ^a   Lombardi, F ^a   Mugelli, A ^a   Urso, R ^a   Scardi, S ^a   Fabbri, G ^a   Bartolomei, B ^a   Barbato, G ^a   Carbonieri, E ^a   Ciricugno, S ^a   Cosmi, F ^a   Pratola, C ^a   Rossi, M G ^a   Sciarra, L ^a   Zeni, P ^a   Ceseri, M ^a   Atzori, A ^a   Bambi, F ^a   Baviera, M ^a   Bianchini, F ^a   Fenicia, E ^a   Gianfriddo, M ^a   Lonardo, G ^a   Luise, A ^a   Nota, R ^a   Orlando, M E ^a   Petrolo, R ^a   Pierattini, C ^a   Pierota, V ^a   Ragno, A ^a   Serio, C ^a   Tafi, A ^a   Tellaroli, E ^a   Masson, S ^a   Vago, T ^a   Gramenzi, S ^a   Orso, F ^a   Suliman, I ^a   Nicolis, E ^a   Casola, C ^a   Dall'Osso, D ^a   Gorini, M ^a   Bianchini, E ^a   Cabiddu, S ^a   Cangioli, I ^a   Carnaghi, A ^a   Cipressa, M L ^a   Cipressa, L ^a   Galbiati, L ^a   Lorimer, A ^a   Priami, P ^a   Moccetti, T ^a   Vaghi, F ^a   Capello, A F ^a   Rossetti, G ^a   Viada, E ^a   Morena, L ^a   Delucchi, M ^a   Reynaud, S G ^a   Allemano, P ^a   Massobrio, N ^a   Gavazzi, A ^a   Taddei, F ^a   Mor, D A ^a   Bortolini, F ^a   Lorini, M ^a   Inama, G ^a   Durin, O ^a   Pirelli, S ^a   Spotti, A ^a   Procopio, R ^a   Cuzzucrea, D ^a   Gentile, G ^a   Margonato, A ^a   Bassanelli, G ^a   Tavazzi, L ^a   Buzzi, M P ^a   Rordorf, R ^a   Gualco, A ^a   Opasich, C ^a   Gronda, E ^a   Genovese, L ^a   Mattioli, R ^a   Donatelli, F ^a   Uriarte, J A ^a   Rauhe, W ^a   Bertagnolli, C ^a   Canestrini, S ^a   Stefenelli, C ^a   Cioffi, G ^a   Giovanelli, C ^a   Rigatelli, G ^a   Boni, S ^a   Pasini, A ^a   Sitta, N ^a   Sacchetta, A ^a   Borgese, L ^a   Sciascia, R ^a   Targa, L ^a   Raviele, A ^a   Madalosso, M ^a   Bertaglia, E ^a   Zoppo, F C ^a   Capanna, M ^a   Fiorencis, R ^a   Baracca, E ^a   Rossi, R ^a   Rossi, I ^a   Trappolin, R ^a   Morgera, T ^a   Barducci, E ^a   Baldin, M G ^a   Gobbo, G ^a   Zardo, F ^a   Hrovatin, E ^a   Mos, L ^a   Vriz, O ^a   Sinagra, G ^a   Aleksova, A ^a   Mazzone, C ^a   Fresco, C ^a   Rubartelli, P ^a   Moroni, L A ^a   Camerieri, A ^a   Piana, M ^a   Mureddu, R ^a   Bertoli, D ^a   Petacchi, R ^a   Pancaldi, L G ^a   Gabrieli, L ^a   Urbinati, S ^a   Pedone, C ^a   Di Niro, M ^a   Brunelli, A ^a   Bosi, S ^a   Censi, S ^a   Moruzzi, P ^a   Pastori, P ^a   Modena, M G ^a   Malavasi, V ^a   Mezzetti, M ^a   Melandri, F ^a   Zuppiroli, A ^a   Fazi, A ^a   Testa, R ^a   Venturini, E ^a   Mazzinghi, F ^a   Cosmi, D ^a   Santoro, G M ^a   Minneci, C ^a   Galli, M ^a   Paperini, L ^a   Bovenzi, F M ^a   Cortigiani, L ^a   Cocchieri, M ^a   Severini, D ^a   Arcuri, G M ^a   Bagliani, G ^a   Bernardinangeli, M ^a   Proietti, G ^a   Bocconcelli, P ^a   Pierantozzi, A ^a   Monti, F ^a   Giamundo, L ^a   Tancredi, P ^a   Rossini, E ^a   Bianchi, C ^a   Bettiol, F ^a   Giovannini, E ^a   Fera, M S ^a   Santini, M ^a   Bianconi, L ^a   Boccanelli, A ^a   Morosetti, P ^a   Volpe, M ^a   Facciolo, C ^a   Vacri, A ^a   Romanazzi, F ^a   Napoletano, C ^a   Piccioni, L L ^a   Candelmo, F ^a   De Marco, G ^a   Arnese, M R ^a   Vetrano, A ^a   Prinzi, D ^a   De Rosa, P ^a   Capuano, V ^a   Torre, S ^a   D'Onofrio, A ^a   Ammendola, E ^a   Chiariello, M ^a   Filardi, PP ^a   Battista, R ^a   De Fusco, A ^a   Molero, U ^a   Iervoglini, A ^a   Stefanelli, S ^a   Fattore, L ^a   Bosco, B ^a   Liguori, A ^a   Padula, G ^a   De Luca, I ^a   Sorino, M ^a   Colonna, P ^a   D'Agostino, C ^a   Pierfelice, O ^a   Pettinati, G ^a   Muscella, A ^a   De Lorenzi, E ^a   Falco, M ^a   Giannattasio, C ^a   Baldi, N ^a   Clemente, M A ^a   D'Alessandro, B ^a   Truncellito, L ^a   Arabia, F ^a   Ciconte, V A ^a   Perticone, F ^a   Ruberto, C ^a   Buffon, A ^a   Tomaselli, C ^a   De Rosa, F ^a   Mazza, S ^a   Zampaglione, G ^a   Pirozzi, A M ^a   Butera, A ^a   Levato, M ^a   Musacchio, D ^a   Polimeni, R M ^a   Lacquaniti, V ^a   Pulitano, G ^a   Ruggeri, A ^a   Provenzano, A ^a   Cuccurullo, O ^a   Musolino, M ^a   Marrari, A ^a   Anastasio, L ^a   Schiavello, M ^a   Comito, M G ^a   Gulizia, M M ^a   Francese, G M ^a   Vasquez, L ^a   Coppolino, C ^a   Casale, A ^a   D'Urso, G ^a   Oliva, G ^a   Giordano, U ^a   Andolina, S ^a   Sanfilippo, N ^a   Ingrilli, F ^a   Accardo, S ^a   Grasso, S ^a   Buffa, L ^a   Serra, E ^a   Disertori, Marcello ^b   Latini, Roberto ^c   Barlera, Simona ^c   Franzosi, Maria Grazia ^c   Staszewsky, Lidia ^c   Maggioni, Aldo Pietro ^d   Lucci, Donata ^d   Di Pasquale, Giuseppe ^e   Tognoni, Gianni ^f   more..

^a Santa Chiara Hospital ^*

^b SANTA CHIARA HOSPITAL   (Italy)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d ANMCO RESEARCH CENTER   (Italy)

^e MAGGIORE HOSPITAL   (Italy)

^f ANMCO Research Center ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; SOTALOL; VALSARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; DRUG DERIVATIVE; TETRAZOLE DERIVATIVE; VALINE;

AGED; ARTICLE; ASTHENIA; CARDIOVERSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; HAIR LOSS; HEART ATRIUM FIBRILLATION; HUMAN; HYPERKALEMIA; HYPOTENSION; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SIDE EFFECT; SINUS RHYTHM; SKIN ALLERGY; TREATMENT OUTCOME; VERTIGO; CARDIOMEGALY; CARDIOVASCULAR DISEASE; COMORBIDITY; DIABETES MELLITUS; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ATRIAL FIBRILLATION; CARDIOMEGALY; CARDIOVASCULAR DISEASES; COMORBIDITY; DIABETES MELLITUS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECURRENCE; TETRAZOLES; VALINE;

EID: 64749085587     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa0805710     Document Type: Article

References (34)

1. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: the Framingham Study. N Engl J Med 1982;306:1018-1022
2. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA 2001;285:2370-2375
3. Pozzoli M, Cioffi G, Traversi E, Pinna GD, Cobelli F, Tavazzi L. Predictors of primary atrial fibrillation and concomitant clinical and hemodynamic changes in patients with chronic heart failure: a prospective study in 344 patients with baseline sinus rhythm. J Am Coll Cardiol 1998;32:197-204. (Pubitemid 28351062)
4. Dries DL, Exner DV, Gersh BJ, Domanski MJ, Waclawiw MA, Stevenson LW. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. J Am Coll Cardiol 1998;32:695-703. (Pubitemid 28435256)
5. Mathew J, Hunsberger S, Fleg J, McSherry F, Williford W, Yusuf S. Incidence, predictive factors, and prognostic significance of supraventricular tachyarrhythmias in congestive heart failure. Chest 2000;118:914-922
6. Køber L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008;358:2678-2687
7. Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med 2000;342:913-920
8. Lafuente-Lafuente C, Mouly S, Longás-Tejero MA, Mahé I, Bergmann JF. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch Intern Med 2006;166:719-728
9. Cappato R, Calkins H, Chen SA, et al. Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation 2005;111:1100-1105
10. Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation- executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). Eur Heart J 2006;27:1979-2030. [Erratum, Eur Heart J 2007;28:2046.]
11. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation: a study in awake chronically instrumented goats. Circulation 1995;92:1954-1968.
12. Nattel S, Li D. Ionic remodeling in the heart: pathophysiological significance and new therapeutic opportunities for atrial fibrillation. Circ Res 2000;87:440-447
13. Daoud EG, Marcovitz P, Knight BP, et al. Short-term effect of atrial fibrillation on atrial contractile function in humans. Circulation 1999;99:3024-3027
14. Shi Y, Li D, Tardif JC, Nattel S. Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure. Cardiovasc Res 2002;54:456-461 (Pubitemid 34327924)
15. Kumagai K, Nakashima H, Urata H, Gondo N, Arakawa K, Saku K. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 2003;41:2197-2204 (Pubitemid 36724267)
16. Li D, Shinagawa K, Pang L, et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 2001;104:2608-2614
17. Chen YJ, Chen YC, Tai CT, Yeh HI, Lin CI, Chen SA. Angiotensin II and angiotensin II receptor blocker modulate the arrhythmogenic activity of pulmonary veins. Br J Pharmacol 2006;147:12-22. (Pubitemid 43069092)
18. Pizzetti F, Turazza FM, Franzosi MG, et al. Incidence and prognostic significance of atrial firbrillation in acute myocardial infarction: the GISSI-3 data. Heart 2001;86:527-532 (Pubitemid 32999863)
19. Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999;100:376-380 (Pubitemid 29362407)
20. Vermes E, Tardif JC, Bourassa MG, et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 2003;107:2926-2931
21. Wachtell K, Lehto M, Gerdts E, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005;45:712-719
22. Maggioni AP, Latini R, Carson PE, et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005;149:548-557
23. Ducharme A, Swedberg K, Pfeffer MA, et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 2006;152:86-92.
24. Schmieder RE, Kjeldsen SE, Julius S, McInnes GT, Zanchetti A, Hua TA. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. J Hypertens 2008;26:403-411
25. Madrid AH, Bueno MG, Rebollo JM, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 2002;106:331-336
26. Yin Y, Dalal D, Liu Z, et al. Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation. Eur Heart J 2006;27:1841-1846.
27. Fogari R, Mugellini A, Destro M, et al. Losartan and prevention of atrial fibrillation recurrence in hypertensive patients. J Cardiovasc Pharmacol 2006;47:46-50.
28. Tveit A, Grundvold I, Olufsen M, et al. Candesartan in the prevention of relapsing atrial fibrillation. Int J Cardiol 2007;120:85-91.
29. Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin- converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005;45:1832-1839.
30. Anand K, Mooss AN, Hee TT, Mohiuddin SM. Meta-analysis: inhibition of renin-angiotensin system prevents newonset atrial fibrillation. Am Heart J 2006;152:217-222 (Pubitemid 44093401)
31. Disertori M, Latini R, Maggioni AP, et al. Rationale and design of the GISSI-Atrial Fibrillation Trial: a randomized, prospective, multicenter study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence. J Cardiovasc Med 2006;7:29-38.
32. Tieleman RG, Van Gelder IC, Crijns HJ, et al. Early recurrences of atrial fibrillation after electrical cardioversion: a result of fibrillation-induced electrical remodeling of the atria? J Am Coll Cardiol 1998;31:167-173
33. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-988
34. Hart RG, Pearce LA, Anguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857-867